secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vistagen Therapeutics, Inc. (VTGN)
CIK:        0001411685
Form:       8-K
Filed at:   2026-04-13T23:59:59+00:00
Accession:  0001628280-26-024943
Event type: other
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Vistagen grants 75,000-share options to CEO, CFO, and three other executives at $0.5358
--------------------------------------------------------------------------------

- Options granted to five executives: CEO Shawn Singh, CLO Reid Adler, CDO Elissa Cote, COO Joshua Prince, CFO Nick Tressler.
- Each option covers 75,000 shares; exercise price $0.5358 per share.
- Vesting: 25% at 6 months, then 25% every 6 months thereafter, fully vested in 2 years.
- Granted under Amended and Restated 2019 Omnibus Equity Incentive Plan.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1411685/000162828026024943/0001628280-26-024943-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1411685/000162828026024943/vtgn-20260407.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-024943

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer